ABSTRACT: Studies using dietary supplementation of eicosapentaenoic and docosahexaenoic fatty acids (FA) in horses report inconsistent anti-infl ammatory results but consistently report an increase in plasma arachidonic acid (C20:4), the major substrate of cyclooxygenase (COX) II infl ammatory pathway. Conjugated linoleic acid has shown anti-infl ammatory effects in laboratory and food animal species, but effects of CLA supplementation in horses have not been reported. Our objective was to determine the effects of CLA supplementation on plasma CLA and C20:4 and body fat in healthy horses at maintenance. In a crossover study, 12 mature mares were blocked by breed, age, and BCS and separated into 2 treatment groups (n = 6/group). Groups were fed CLA and corn oil (CO; isocaloric control) for two 6-wk feeding periods, separated by a 4-wk period during which treatment was withheld. Corn oil or CLA supplement (55% mixed CLA isomers) was incorporated into diets at 0.01% BW/d. Mares were fed individually and restricted to dry lots to control forage intake. Rump fat thickness (RFT), BW, and BCS were measured before (d 0) and after (d 42) each feeding period. Blood was collected on d 0, 14, 28, and 42 of each 6-wk period for GLC analysis of plasma CLA isomers (cis-9, trans-11; trans-10, cis-12; and trans-9, trans-11) and C20:4. An ANOVA was conducted to compare the response of RFT, BW, and BCS of CLA-treated and control mares. A mixed methods analysis with repeated measures was used to detect differences in plasma FA concentrations. There were no differences in BW, RFT, or BCS between treatment groups. All CLA isomers present in the CLA supplement were greater in plasma of horses fed CLA compared with controls (P < 0.01). Additionally, plasma concentrations of C20:4 were decreased in horses fed CLA (P < 0.05). This decline in C20:4 may impact the COX II pathway and warrants further investigation. These results suggest that in an equine model, dietary CLA increases circulating concentrations of supplemented CLA isomers and decreases circulating C20:4. Examining physiological effects of CLA supplementation in horses at varying levels of growth, exercise, and progression of joint disease may offer insight to potential benefi ts of CLA in the horse.
INTRODUCTION
Recently, because of their putative anti-infl ammatory effects, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been supplemented to horses at maintenance (Hansen et al., 2002; Hall et al., 2004; King et al., 2008) , exercised horses (O'Connor et al., 2004; Woodward et al., 2007) , and horses with osteoarthritis (Manhart et al., 2009) . King et al. (2008) described the dose-dependent accretion of supplemental DHA and EPA in plasma and subsequent decrease of these fatty acids (FA) in plasma after their removal from the diet.
Conjugated linoleic acid is the collective group of 18-C FA isomers with a conjugated, 2 double bond system, and 1 specifi c isomer, trans-10, cis-12 CLA, has been shown to interact with BW and body fat (Park et al., 1999) . Inclusion of CLA at 0.009 g CLA/kg BW in humans, 1.9% of the diet in broiler chicks, and 1% of the diet in swine caused an increase of CLA in serum or tissues (Stangl et al., 1999; Simon et al., 2000; Mougios et al., 2001 ). Supplementation of CLA for 8 wk in humans and 6 wk in swine also caused serum concentrations of arachidonic acid (C20:4) to decrease (Stangl et al., 1999; Mougios et al., 2001) .
However, the effects of CLA supplementation on plasma FA concentration or biological impact in horses have not been published. Therefore, the goal of this investigation was to describe the effect of dietary CLA supplementation on plasma concentrations of CLA isomers and C20:4 and body fat in horses in preparation for future study on the effects of CLA in models of equine joint disease or increased exercise.
MATERIALS AND METHODS
This research was approved by the Institutional Animal Care and Use Committee of Clemson University (Animal Use Protocol no. 2009-067) .
Experimental Design
In a crossover study, light horse mares (n = 12; Quarter Horse, Thoroughbred, and Quarter Horse crossbred), 2 to 19 yr in age and 510 to 645 kg BW, were pair-matched by breed, age, and BCS and randomly assigned to 2 groups (n = 6/group). The crossover study consisted of 2 dietary treatments fed over two 6-wk feeding periods, which were separated by a 4-wk washout period in which treatment was withheld. Dietary treatments consisted of CLA or corn oil (CO) supplementation.
It has been reported that FA (EPA and DHA) supplementation for a duration of 6 wk at a rate of 0.002 to 0.008% BW daily is an adequate supplementation rate and duration of time for the dietary FA to increase or become detectable in circulating plasma of horses (King et al., 2008) . The same study showed a decrease in circulating concentrations of the supplemented FA by 9 d after cessation of FA supplementation (King et al., 2008) . Based on this, a feeding duration of 6 wk/feeding period and a total CLA isomer inclusion rate of 0.0055% BW/d were selected for the current study.
Diets
Before the start of the study, all mares were group housed on pasture, with access to round bale coastal bermudagrass hay, and were fed the same commercially prepared concentrate feed as used in this study. The only change in the diet was the inclusion of the aforementioned oil treatments.
All mares were fed isocalorically and isonitrogenously. Diets were designed to fulfi ll maintenance energy requirements of the average horse (NRC, 2007) . The daily ration consisted of coastal bermudagrass hay (Cynodon dactylon) fed at a rate of 1.5% BW (as-fed), a commercially available textured grain (Reliance 11; Southern States Cooperative, Richmond, VA) fed at 0.3% BW (as-fed), and a top-dressed oil supplement (CLA or CO treatment) fed at 0.01% BW (as-fed). The CLA source (BASF Corp., Florham Park, NJ) provided 55% CLA (mixture of cis-9, trans-11; trans-10, cis-12 ; and trans-9, trans-11 CLA isomers), yielding a CLA supplementation rate of 0.0055% BW (as-fed). During the washout period, oil was removed from the diet and each mare was fed to achieve original d 0 BCS. Daily diets were separated into 2 meals and fed at 0600 and 1600 h daily. There were no signifi cant refusals of diets or treatments. Each mare was fed the daily ration in an individual stall. Between meals, mares were housed on drylots (approximately 6 × 10 m; 3 to 4 mares each) to prevent excessive exercise and allow free access to water and trace mineralized salt blocks.
Diet Adaptation
Before the start of the experiment (d -6), mares began receiving oil to acclimate them to the oil treatment. On d -6, mares received 25% of the fi nal treatment dose. Allotted daily oil increased by 25% of the total oil treatment dose every 2 d so that mares received the full oil ration (CO or CLA) on d 0 of the trial. This procedure was completed in a step-down manner at the end of each feeding period, beginning on d 42 of full oil supplementation.
Biological Sampling
Blood was collected (10 mL) via jugular veinipuncture into evacuated tubes containing K 2 EDTA (Becton-Dickinson, Franklin Lakes, NJ) at 0600 h from fasted mares on d 0 of the trial and weekly thereafter throughout the trial, including the washout period. Once collected, blood for plasma FA analysis was stored at 4°C overnight and then centrifuged at 1,300 × g for 10 min between 4 and 10°C.
Body Composition
Horses were weighed in a fasting state at 0600 h on a digital livestock scale (A and A Scales, LLC , Prospect Park, NJ) on d 0 and weekly thereafter throughout the trial for weekly adjustment of diets. Body condition scores of mares were assessed by the same trained individual on d 0 and weekly thereafter throughout the trial using procedures described by Henneke et al. (1983) . Rump fat thickness (RFT; cm) was determined via transdermal ultrasonography (Aloka 500V, probe model U51 5011U-3.5; Aloka Inc., Tokyo, Japan) before (d 0) and after (d 42) each feeding period at a point midway between the top of the croup and the tailhead, 5 cm dorsal of halfway between the fi rst coccygeal vertebrae and the ischium as previously described (Westervelt et al., 1976) .
Chemical Analysis
Textured grain, hay, and both oil supplements were analyzed by GLC for concentration of CLA isomers and C20:4 (Table 1) . Textured grain and hay were ground to 0.5 μm before being lyophilized. Frozen plasma and diet samples were lyophilized in original culture tubes (Lyph-Lock 6; Labconco Corp., Kansas City, MO), screw caps were reapplied, and freeze-dried samples were maintained at -20°C. Fatty acids were converted to FA methyl esters by a previously described 2-step methylation procedure (Jenkins, 2010) using tricosylic acid (C23:0) in toluene as an internal standard. Fatty acid methyl esters were stored at -20°C until analysis by GLC. Individual FA methyl esters were separated by GLC on a 100 m × 0.25 mm × 0.2 μm column (Supelco SP-2560; Sigma-Aldrich, St. Louis, MO) and detected by a fl ame ionization detector.
Statistical Analyses
All data sets were checked for outliers, normality, constant variance, and if applicable, independence of error terms. An ANOVA was conducted to compare body fat variable responses between CLA and CO group means. The change in the measurement of a variable from pretrial to posttrial (d 42 to d 0) was used as the response variable in the analysis. The model for the crossover analysis also included fi xed effects of feeding period and sequence of treatment administration and the random effect of individual mare. Student t-tests were conducted to identify differences between treatments or feeding periods on a d (d 0 or d 42).
Fatty acid data were analyzed using a mixed methods analysis (SAS Inst. Inc., Cary, NC) with an unstructured covariance structure for repeated measures (Littell et al., 2006) to test the signifi cance of the fi xed effects of sequence of treatment, feeding period, treatment, day, and treatment × day interaction, with individual horse nested within sequence as a random effect. Additionally, paired t-tests were conducted to determine differences in mean plasma FA between treatment groups on any single day and to determine differences in mean plasma FA concentration between day for any single treatment group. Concentrations of plasma FA that were not detectable were analyzed as 0 values. The GLC detection limit was 250 mV. Statistical signifi cance was established with α = 0.05, and trends toward signifi cance were noted with 0.1 < α < 0.05.
RESULTS

Body Composition
Conjugated linoleic acid supplementation did not have an effect on BW, BCS, or RFT compared with mares fed CO. Table 2 contains mean BW, BCS, and RFT for mares consuming CLA or CO at d 0 and d 42 of feeding and difference in measurement (d 42 to d 0) over the feeding period. Neither BW nor BCS were affected by treatment, treatment sequence, or feeding period. Change in RFT tended to increase in mares (P = 0.075) as a result of CLA treatment. Rump fat thickness was not affected by sequence of treatment administration or feeding period.
Plasma Fatty Acids
Plasma FA concentrations for all 3 supplemented CLA isomers were increased (P < 0.001) in supplemented mares compared with CO (Table 3) . Conjugated linoleic acid isomers were not detectable in plasma of control mares during the feeding periods (Table 3) .
Plasma cis-9, trans-11 CLA concentrations increased and plateaued, despite numerical differences, by d 14 in period 1 and by d 28 in period 2 (P < 0.001) in supplemented mares. However, they remained nondetectable in CO mares, resulting in a treatment × day interaction (P < 0.001; Table 3 ). Although a comparison of average cis-9, trans-11 CLA concentrations on d 28 and 42 in CLA supplemented horses in period 1 may appear to be different, they were not different (P > 0.050). Despite plasma cis-9, trans-11 CLA reaching maximum concentrations by d 14 in period 1 and by d 28 in period 2, there was no period effect or sequence effect for this isomer (Table 3) .
Similarly to cis-9, trans-11 CLA, plasma concentrations of trans-10, cis-12 CLA increased and plateaued by d 14 in period 1 and by d 28 in period 2 for supplemented mares but remained nondetectable in control mares throughout the experiment, resulting in a treatment × day interaction as well as a day effect (P < 0.001; Table 3 ). Because of the difference between periods 1 and 2 in accretion times for trans-10, cis-12 CLA in plasma, there was a period effect (P = 0.014) as well as a sequence effect (P = 0.030), with mares receiving CO fi rst and then CLA showing slower accretion times (28 d) compared with mares receiving CLA fi rst and then CO (14 d; Table 3 ).
In period 1, plasma trans-9, trans-11 CLA concentrations increased in supplemented mares until d 14 and plateaued at approximately 1.3% of total plasma FA for the remainder of supplementation (Table 3) . In period 2, plasma concentrations of trans-9, trans-11 CLA in supplemented mares increased to more than 1.6% of total plasma FA and plateaued by d 14 (Table 3) . The increase and plateau behavior of trans-9, trans-11 CLA concentrations results in a day effect (P < 0.001) as well as a treatment × day interaction (P < 0.001), as the CO mares did not have detectable plasma concentrations of the isomer throughout the study (Table 3) . Mares consuming CLA in period 1 had decreased d 0 trans-9, trans-11 CLA concentrations compared with CLA mares in period 2 (P = 0.029), which, along with the difference in maximum concentration between periods, resulted in a period effect for trans-9, trans-11 CLA concentrations (P < 0.001). Furthermore, differences between periods in CLA mares also resulted in a sequence effect (P = 0.004) for the trans-9, trans-11 CLA isomer.
Mares consuming CLA exhibited decreased plasma C20:4 concentrations compared with controls on d 14, 28, and 42 in period 1 and on d 42 in period 2 (P < 0.001; Figure 1 ). Arachidonic acid concentrations did exhibit a treatment × day interaction (P = 0.003), which is evidenced in period 2 and is a result of plasma C20:4 for CLA-treated horses decreasing until d 28 and then remaining constant until d 42 whereas plasma C20:4 for controls initially decreased but then increased from d 28 to d 42 (Figure 1 ). Plasma C20:4 decreased over time for both CO and CLA supplemented mares (day effect P < 0.001). The period effect (P < 0.001) for plasma C20:4 is evidenced in lower d 0 C20:4 concentrations in period 2 (P < 0.001) compared with period 1, regardless of treatment.
DISCUSSION
The purpose of this study was to investigate if dietary CLA would change body composition and body fat distribution as well as alter the plasma FA profi le in the horse. To our knowledge these data did not previously exist. Although there are data on the effects of dietary n-3 supplements in the form of fi sh oils, the role of CLA has not been investigated in the horse. Conjugated linoleic acid may confer health benefi ts in the horse as found in other animal models; however, it had yet to be determined if dietary CLA would be absorbed and available to incorporate into other body tissues. To compare the fat source of dietary CLA in the horse, CO was chosen as the control as it is the most commonly used source of additional DE in equine diets and is a palatable source for an isocaloric control. Additionally, when reviewing previous equine literature evaluating the use of various oil sources to modify the omega 3 to omega 6 ratios and their ability to potentially impact infl ammation, CO is a commonly used source to create diets high in omega 6 content and maintain isocaloric treatments. Studies that investigated similar hypotheses of n-3 versus n-6 (EPA or fi sh oils) on C20:4 and other plasma FA commonly used CO as the control. These n-3 PUFA (e.g., fi sh oil) behave similarly to CLA in terms of antiinfl ammatory properties and competition with linoleic acid for production of C20:4.
Body Composition
Results of this study indicate that CLA supplementation does not have an effect on BW or BCS but may affect RFT at the stated plane of nutrition and metabolic requirements of the experimental units, CLA inclusion rate, and CLA supplementation length. The specifi c CLA isomer known for anti-adipogenic properties, trans-10 cis-12, was present in the CLA supplement and increased in the circulating plasma of supplemented horses. Thiel-Cooper et al. (2001) demonstrated that CLA supplementation in growing-fi nishing hogs caused increased ADG, decreased 10th rib backfat, decreased fat depth over the loin eye at the 10th rib, and decreased intermuscular and subcutaneous fat. The mares in the current study, however, were in a physiological state of maintenance, not of skeletal or muscular development compared with growing-fi nishing pigs, which could contribute to the difference in results between these studies. Additionally, the supplementation rate of CLA in hogs was greater (up to 1.0% of the total diet; Thiel-Cooper et al., 2001 ) compared with the current experimental diet in which CLA isomers were 0.30% of diet as-fed. The data from the current study indicating that CLA tends to increase RFT in mares are in contrast with data from aforementioned studies demonstrating that the trans-10, cis-12 CLA isomer changes body composition by decreasing body fat. Further study is needed to clarify the reason for the confl icting results.
Plasma Fatty Acids
Effects of CLA supplementation have been reported in ruminants and nonruminants in lab animal and production species as well as humans. Mougios et al. (2001) observed effects on FA profi le of serum lipids and percent body fat and body fat mass, when healthy, adult humans were supplemented with 0.7 g CLA for 4 wk and then with 1.4 g CLA for the next 4 wk. Compared with controls that consumed placebo, CLA content in serum lipid classes increased gradually throughout supplementation, and C20:4 decreased in serum phospholipids in CLA-treated individuals (Mougios et al., 2001) . Serum triglycerides and total cholesterol tended to decrease in the fi rst supplementation period, and total body fat mass and body fat percentage decreased in the CLA group by the end of the 8-wk supplementation (Mougios et al., 2001) .
A study in broilers reported greater CLA content in liver and abdominal fat, breast and leg muscle, and heart tissue of animals fed a diet containing 18.7 g CLA/kg diet for 42 d compared with controls fed a linoleic acid supplement (Simon et al., 2000) . Supplementation of mature, female pig diets with 1% of a CLA supplement for 6 wk caused an increase in fasting serum CLA concentrations and a decrease in fasting serum C20:4 concentrations compared with controls but did not cause differences in BW (Stangl et al., 1999) . The results of our study agree with the general observations of these studies, which indicate that in monogastrics, dietary CLA is absorbed and incorporated in circulation when fed at up to 1% of the diet for 6 to 8 wk.
The detectability and steep increase of CLA isomers in plasma follows the general trend for FA accretion reported by King et al. (2008) when DHA and EPA were supplemented to horses at 0, 10, 20, or 40 g/d for 28 d. In the current study, circulating CLA isomer concentrations peaked and plateaued by d 14 in feeding period 1 and by d 28 in feeding period 2 (except for trans-9, trans-11 CLA, which peaked by d 14 in period 2). Despite similar FA dosage rates, DHA and EPA concentrations consistently peaked at d 7 (King et al., 2008) . The delay of maximum plasma concentrations of cis-9, trans-12 and trans-10, cis-12 isomers in feeding period 2 compared with feeding period 1 could be an effect of the crossover design. Although the 4-wk washout period was suffi cient for CLA to decline in treated horses (on d 0 of period 2, CLA was not detectable in control mares that had consumed CLA in period 1), there may be lasting effects of FA supplementation on lipid metabolism or the ability to competitively incorporate new dietary FA into circulation.
The fi nding that supplemented FA can affect circulating plasma FA after 7 d of supplementation (King et al., 2008) supports our fi nding that horses in the CLA supplemented group but not the CO group showed detectable concentrations of CLA in circulating plasma at d 0 after a CLA supplement acclimation period beginning d -6. Plasma samples were not collected before d 0 of the feeding period as a baseline to confi rm CLA was not detectable in circulating plasma of mares in the CLA group. However, the crossover design allowed all 12 mares to experience both treatments, and no mare that showed detectable plasma CLA on d 0 of the CLA-supplementation period had detectable plasma CLA at d 0 of their CO-supplementation period, 4 wk after cessation of CLA supplementation. Additionally, King et al. (2008) reported CLA to be nondetectable in all of their horses (n = 16) across treatments and days. Therefore it is unlikely that treatment and control groups differed in circulating concentrations of CLA isomers on d -6 of each feeding period when mares began receiving small amounts of supplemental oil. This fi nding indicates that 4 wk is suffi cient for plasma CLA concentrations to return to presupplemental concentrations after removal of the CLA source from the diet, which is supported in n-3 FA supplementation studies in horses (Hall et al., 2004; King et al., 2008) .
Of the isomers detected in the CLA supplement, cis-9, trans-11 and trans-10, cis-12 CLA had concentrations proportional to each other in the supplement and in circulation. However, the trans-9, trans-11 isomer was less than one-tenth of the concentration of either of the cis-, trans-or trans-, cis-isomers within the supplement but was 1.5 times greater than the other supplemental isomers in circulating plasma. Although we expected CLA isomers to have the same distribution in circulation as in the CLA supplement, there are possible explanations for this phenomenon. It is possible that the trans-, trans-geometric structure of the isomer alters its absorption or metabolism within the body. Most CLA studies are directed toward the cis-9, trans-11 and trans-10, cis-12 CLA isomers; however, some studies have reported the inclusion of trans-9, trans-11 CLA. Kramer et al. (1998) fed a commercial CLA supplement containing cis-, trans-isomers (82%), trans-, trans-isomers (10.1%), and cis-, cis-isomers (7.4%) to pigs and examined tissue for the distribution of CLA isomers. Inner backfat, omental fat, FFA, and liver triacylglycerols of pigs fed the CLA supplement all had CLA distributions similar to the supplement. Interestingly, CLA distributions in other tissue lipid classes, such as liver and heart phospholipids, deviated from the CLA distribution of the supplement (Kramer et al., 1998) . A group of 3 trans-, trans-isomers (trans-10, trans-12; trans-9, trans-11; and trans-8, trans-10) was reported to be 3 times more concentrated (as a percentage of total CLA isomers) in liver and heart FFA in comparison with the diet (Kramer et al., 1998) . The authors suggested trans-, trans-CLA isomers are metabolized more slowly than cis-, trans-isomers and therefore accumulate in the FFA form, which supports our fi nding in the current study.
Increase of circulating trans-9, trans-11 isomer to greater than the concentrations of cis-9, trans-11 and trans-10, cis-12 does not necessarily negate the physiological effects of these 2 cis-, trans-isomers in our study. These isomers may have been readily incorporated into tissues for use, explaining their decreased concentrations in plasma. Although reports on the physiologic effects of trans-9, trans-11 CLA are few, Park et al. (1999) found that the trans-9, trans-11 CLA isomer had no effect on lipoprotein lipase activity or on intracellular triacylglycerol or glycerol concentrations in cultured 3T3-L1 adipocytes. The authors suggested trans-9, trans-11 CLA is not the CLA isomer responsible for changing body composition. More research is required to investigate other physiological effects of trans-9, trans-11 CLA.
The infl uence of various supplemental fat sources on C20:4 concentrations in the horse is highly variable and dependent on source. The current investigation observed a decrease in plasma C20:4 concentrations in mares consuming CLA. When Hall et al. (2004) supplemented fi sh oil at 3.0% of the diet (as-fed), circulating C20:4 concentrations were increased in horses consuming fi sh oil by d 7 of supplementation, which persisted throughout. In a different study, exercised horses were supplemented with 3 mg/kg BW EPA and 7 mg/kg BW DHA per d for 75 d (Woodward et al., 2007) . Plasma DHA but not EPA increased in treated horses compared with controls. Additionally, C20:4 was greater in plasma of horses consuming the n-3 FA diet compared with controls on d 50 and 75 (Woodward et al., 2007) . Exercising horses fed fi sh oil for 63 d had no change in C20:4 concentrations by the end of the study . Likewise, horses fed a diet enriched with fl axseed oil showed no differences in C20:4 concentrations compared with the control diet (Hansen et al., 2002) . The authors of that study attributed this to the fact that they had an inadequate n-3:n-6 ratio (Hansen et al., 2002) .The role of the reduced plasma C20:4 concentrations in this study on PGE2 pathways and effects on FA composition of other tissues remains unclear.
Plasma concentrations of C20:4 as well as trans-10, cis-12 CLA and trans-9, trans-11 CLA were affected by feeding period within the crossover design. In feeding period 1, CLA isomers reached peak concentrations by d 14 and plateaued; however, in feeding period 2, trans-9, trans-11 CLA was the only isomer to reach its peak concentration by d 14. The other isomers (cis-9, trans-11 and trans-10, cis-12) reached peak concentrations by d 28. Both of these accretion times are substantiated in literature (Hall et al., 2004; King et al., 2008) , but the fact that the feeding periods behave differently may indicate that although a washout period of 4 wk is long enough for supplemental CLA to clear from circulation, effects of FA supplementation may affect overall lipid metabolism and metabolism of dietary CLA isomers for a longer duration of time.
An additional difference between feeding periods is apparent in plasma FA concentrations at d 0 for all 4 FA analyzed. At d 0 of feeding period 2, cis-9, trans-11 CLA and trans-10, cis-12 CLA were both detectable in CLAtreated mares (which consumed CO in period 1) but were not detectable in mares that consumed CLA in feeding period 1. As previously mentioned, the appearance of CLA in plasma of the CLA group is due to the inclusion of small amounts of the CLA supplement for acclimation beginning on d -6. However, we would have expected both feeding periods to behave similarly, because they were both subjected to the same duration of diet acclimation.
The period effect of plasma C20:4 has 2 probable causes. First, the difference in d 0 values for plasma C20:4 between periods indicates the washout period was insufficient to allow plasma C20:4 concentrations to return to presupplementation concentrations after the decrease in C20:4 observed in feeding period 1 for mares in both treatment groups. Second, plasma C20:4 in feeding period 2 does not show the magnitude of decline observed in feeding period 1 although the decline was still signifi cant. This again may be attributed to a longer lasting effect of FA supplementation, which may alter lipid metabolism even after clearance of the supplemented FA.
Conclusion
Dietary supplementation of CLA at 0.0055% BW/d over two 6-wk feeding periods is shown here to increase circulating concentrations of each of the supplemented CLA isomers and to decrease circulating concentrations of C20:4 but not to affect body fat accretion. At the current CLA inclusion rate and duration of supplementation, CLA is cleared from circulating plasma by 4 wk postsupplementation. Although circulating C20:4 concentrations in mares fed CO decreased over both feeding periods, mares consuming CLA experienced a greater decrease. Studies with longer durations of CLA supplementation may help clarify the cause of the feeding period effects observed in the current study.
